Mutant huntingtin is present in neuronal grafts in huntington disease patients

Annals of Neurology

Volumn 76, Issue 1, 2014, Pages 31-42

  Cicchetti, Francesca ^a,b   Lacroix, Steve ^a,c   Cisbani, Giulia ^a   Vallières, Nicolas ^a   Saint Pierre, Martine ^a   St Amour, Isabelle ^a   Tolouei, Ranna ^c,d   Skepper, Jeremy N ^e   Hauser, Robert A ^f   Mantovani, Diego ^c,d   Barker, Roger A ^g   Freeman, Thomas B ^h,i  

^a Université Laval   (Canada)

^b Departments of Psychiatry and Neurosciences   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h John Van Geest Centre for Brain Repair Department of Clinical Neurosciences University of Cambridge ^*  (United States)

ⁱ UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPITOPE; HUNTINGTIN;

ADULT; ALLOGRAFT; ARTICLE; BLOOD VESSEL; BRIGHT FIELD MICROSCOPY; CASE REPORT; ELECTRON MICROSCOPY; EXTRACELLULAR MATRIX; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INFRARED SPECTROSCOPY; MUTANT; NERVE CELL; NERVOUS TISSUE; NEURAL ALLOGRAFT; NEUROPIL; PRIORITY JOURNAL; PROTEIN AGGREGATION; WESTERN BLOTTING;

ADULT; ALLOGRAFTS; BRAIN TISSUE TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; FETAL TISSUE TRANSPLANTATION; HUMANS; HUNTINGTON DISEASE; MIDDLE AGED; MUTATION; NEOSTRIATUM; NERVE TISSUE PROTEINS;

EID: 84904787076     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24174     Document Type: Article

References (48)

1. Phillips W, Shannon KM, Barker RA,. The current clinical management of Huntington's disease. Mov Disord 2008; 23: 1491-1504.
2. Zuccato C, Valenza M, Cattaneo E,. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010; 90: 905-981.
3. Steffan JS, Kazantsev A, Spasic-Boskovic O, et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 2000; 97: 6763-6768.
4. Ross CA, Tabrizi SJ,. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10: 83-98.
5. Freeman TB, Cicchetti F, Bachoud-Lévi AC, Dunnett SB,. Technical factors that influence neural transplant safety in Huntington's disease. Exp Neurol 2011; 227: 1-9.
6. Peschanski M, Cesaro P, Hantraye P,. Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 1995; 68: 273-285.
7. Isacson O, Brundin P, Kelly PA, et al. Functional neuronal replacement by grafted striatal neurones in the ibotenic acid-lesioned rat striatum. Nature 1984; 311: 458-460.
8. Wictorin K,. Anatomy and connectivity of intrastriatal striatal transplants. Prog Neurobiol 1992; 38: 611-639.
9. Pritzel M, Isacson O, Brundin P, et al. Afferent and efferent connections of striatal grafts implanted into the ibotenic acid lesioned neostriatum in adult rats. Exp Brain Res 1986; 65: 112-126.
10. Deckel AW, Robinson RG, Coyle JT, Sanberg PR,. Reversal of long-term locomotor abnormalities in the kainic acid model of Huntington's disease by day 18 fetal striatal implants. Eur J Pharmacol 1983; 93: 287-288.
11. Freeman TB, Cicchetti F, Hauser RA, et al. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc Natl Acad Sci USA 2000; 97: 13877-13882.
12. Cicchetti F, Saporta S, Hauser RA, et al. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A 2009; 106: 12483-12488.
13. Cisbani G, Freeman TB, Soulet D, et al. Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability. Brain 2013; 136: 433-443.
14. Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 2002; 58: 687-695.
15. Kim M, Soontornniyomkij V, Ji B, Zhou X,. System-wide immunohistochemical analysis of protein co-localization. PLoS One 2012; 7: e32043.
16. Glass G, Papin JA, Mandell JW,. SIMPLE: a sequential immunoperoxidase labeling and erasing method. J Histochem Cytochem 2009; 57: 899-905.
17. Becher MW, Kotzuk JA, Sharp AH, et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 1998; 4: 387-397.
18. Pirici D, Mogoanta L, Kumar-Singh S, et al. Antibody elution method for multiple immunohistochemistry on primary antibodies raised in the same species and of the same subtype. J Histochem Cytochem 2009; 57: 567-575.
19. Addis MF, Tanca A, Pagnozzi D, et al. Generation of high-quality protein extracts from formalin-fixed, paraffin-embedded tissues. Proteomics 2009; 9: 3815-3823.
20. Weiss A, Träger U, Wild EJ, et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J Clin Invest 2012; 122: 3731-3736.
21. Cubillos-Rojas M, Amair-Pinedo F, Tato I, et al. Simultaneous electrophoretic analysis of proteins of very high and low molecular mass using Tris-acetate polyacrylamide gels. Electrophoresis 2010; 31: 1318-1321.
22. André W, Sandt C, Dumas P, et al. Structure of inclusions of Huntington's disease brain revealed by synchrotron infrared microspectroscopy: polymorphism and relevance to cytotoxicity. Anal Chem 2013; 85: 3765-3773.
23. Khare SD, Ding F, Gwanmesia KN, Dokholyan NV,. Molecular origin of polyglutamine aggregation in neurodegenerative diseases. PLoS Comput Biol 2005; 1: 230-235.
24. Graybiel AM, Liu FC, Dunnett SB,. Intrastriatal grafts derived from fetal striatal primordia. I. Phenotypy and modular organization. J Neurosci 1989; 9: 3250-3271.
25. Gutekunst CA, Li SH, Yi H, et al. The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): comparison with huntingtin in rat and human. J Neurosci 1998; 18: 7674-7686.
26. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277: 1990-1993.
27. Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14: 504-506.
28. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008; 14: 501-503.
29. Brundin P, Melki R, Kopito R,. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 2010; 11: 301-307.
30. Soto C,. Transmissible proteins: expanding the prion heresy. Cell 2012; 149: 968-977.
31. Goedert M, Spillantini MG, Del Tredici K, Braak H,. 100 years of Lewy pathology. Nat Rev Neurol 2013; 9: 13-24.
32. Olanow CW, Prusiner SB,. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A 2009; 106: 12571-12572.
33. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009; 106: 13010-13015.
34. Hansen C, Angot E, Bergström A-L, et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011; 121: 715-725.
35. Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338: 949-953.
36. de Calignon A, Polydoro M, Suarez-Calvet M, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012; 73: 685-697.
37. Clavaguera F, Akatsu H, Fraser G, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A 2013; 110: 9535-9540.
38. Liu L, Drouet V, Wu JW, et al. Trans-synaptic spread of tau pathology in vivo. PLoS One 2012; 7: e31302.
39. Cicchetti F, Soulet D, Freeman TB,. Neuronal degeneration in striatal transplants and Huntington's disease: potential mechanisms and clinical implications. Brain 2011; 134: 641-652.
40. Meyer-Luehmann M, Stalder M, Herzig MC, et al. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci 2003; 6: 370-377.
41. Ren P-H, Lauckner JE, Kachirskaia I, et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 2009; 11: 219-225.
42. Cisbani G, Cicchetti F,. The fate of cell grafts for the treatment of Huntington's disease: the post-mortem evidence. Neuropathol Appl Neurobiol 2013; 40: 71-90.
43. Brundin P, Kordower JH,. Neuropathology in transplants in Parkinson's disease: implications for disease pathogenesis and the future of cell therapy. Prog Brain Res 2012; 200: 221-241.
44. Shelbourne PF, Keller-McGandy C, Bi WL, et al. Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain. Hum Mol Genet 2007; 16: 1133-1142.
45. Kennedy L, Evans E, Chen C-M, et al. Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet 2003; 12: 3359-3367.
46. Bouchard J, Truong J, Bouchard K, et al. Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci 2012; 32: 18259-18268.
47. Kwan W, Magnusson A, Chou A, et al. Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J Neurosci 2012; 32: 133-142.
48. Keene CD, Sonnen JA, Swanson PD, et al. Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 2007; 68: 2093-2098.